Logo image of PROK

PROKIDNEY CORP (PROK) Stock Fundamental Analysis

USA - NASDAQ:PROK - US74291D1046 - Common Stock

2.7 USD
-0.1 (-3.57%)
Last: 11/5/2025, 4:30:00 PM
2.76 USD
+0.06 (+2.22%)
After Hours: 11/5/2025, 4:30:00 PM
Fundamental Rating

2

Taking everything into account, PROK scores 2 out of 10 in our fundamental rating. PROK was compared to 534 industry peers in the Biotechnology industry. The financial health of PROK is average, but there are quite some concerns on its profitability. PROK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PROK had negative earnings in the past year.
In the past year PROK has reported a negative cash flow from operations.
In the past 5 years PROK always reported negative net income.
In the past 5 years PROK always reported negative operating cash flow.
PROK Yearly Net Income VS EBIT VS OCF VS FCFPROK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a decent Return On Assets value of -19.48%, PROK is doing good in the industry, outperforming 76.40% of the companies in the same industry.
Industry RankSector Rank
ROA -19.48%
ROE N/A
ROIC N/A
ROA(3y)-14.39%
ROA(5y)-68.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PROK Yearly ROA, ROE, ROICPROK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PROK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PROK Yearly Profit, Operating, Gross MarginsPROK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

4

2. Health

2.1 Basic Checks

PROK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PROK has more shares outstanding
Compared to 1 year ago, PROK has an improved debt to assets ratio.
PROK Yearly Shares OutstandingPROK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
PROK Yearly Total Debt VS Total AssetsPROK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -4.94, we must say that PROK is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.94, PROK is in line with its industry, outperforming 40.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.94
ROIC/WACCN/A
WACC8.77%
PROK Yearly LT Debt VS Equity VS FCFPROK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M -1B

2.3 Liquidity

PROK has a Current Ratio of 11.48. This indicates that PROK is financially healthy and has no problem in meeting its short term obligations.
PROK has a Current ratio of 11.48. This is amongst the best in the industry. PROK outperforms 84.64% of its industry peers.
PROK has a Quick Ratio of 11.48. This indicates that PROK is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PROK (11.48) is better than 84.64% of its industry peers.
Industry RankSector Rank
Current Ratio 11.48
Quick Ratio 11.48
PROK Yearly Current Assets VS Current LiabilitesPROK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

PROK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.39%.
EPS 1Y (TTM)3.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PROK will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.79% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.08%
EPS Next 2Y7.83%
EPS Next 3Y8.55%
EPS Next 5Y9.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PROK Yearly Revenue VS EstimatesPROK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PROK Yearly EPS VS EstimatesPROK Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PROK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PROK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROK Price Earnings VS Forward Price EarningsPROK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PROK Per share dataPROK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.83%
EPS Next 3Y8.55%

More info and screens

0

5. Dividend

5.1 Amount

PROK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROKIDNEY CORP

NASDAQ:PROK (11/5/2025, 4:30:00 PM)

After market: 2.76 +0.06 (+2.22%)

2.7

-0.1 (-3.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10
Inst Owners30.42%
Inst Owner Change-1.24%
Ins Owners1.92%
Ins Owner Change-0.12%
Market Cap794.56M
Revenue(TTM)527.00K
Net Income(TTM)-72474000
Analysts78.57
Price Target5.95 (120.37%)
Short Float %10.84%
Short Ratio5.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.29%
Min EPS beat(2)11.49%
Max EPS beat(2)19.08%
EPS beat(4)3
Avg EPS beat(4)6.08%
Min EPS beat(4)-12.23%
Max EPS beat(4)19.08%
EPS beat(8)6
Avg EPS beat(8)10.19%
EPS beat(12)10
Avg EPS beat(12)25.71%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.17%
EPS NQ rev (1m)2.22%
EPS NQ rev (3m)8.33%
EPS NY rev (1m)2.05%
EPS NY rev (3m)8.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)8.31%
Revenue NY rev (3m)208.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1507.7
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0
BVpS-3.41
TBVpS-3.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.39%
ROA(5y)-68.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 525.06%
Cap/Sales 6102.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.48
Quick Ratio 11.48
Altman-Z -4.94
F-Score2
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)497.21%
Cap/Depr(5y)464.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y18.08%
EPS Next 2Y7.83%
EPS Next 3Y8.55%
EPS Next 5Y9.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.7%
EBIT Next 3Y-2.92%
EBIT Next 5YN/A
FCF growth 1Y-72.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.91%
OCF growth 3YN/A
OCF growth 5YN/A

PROKIDNEY CORP / PROK FAQ

What is the ChartMill fundamental rating of PROKIDNEY CORP (PROK) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PROK.


Can you provide the valuation status for PROKIDNEY CORP?

ChartMill assigns a valuation rating of 0 / 10 to PROKIDNEY CORP (PROK). This can be considered as Overvalued.


What is the profitability of PROK stock?

PROKIDNEY CORP (PROK) has a profitability rating of 1 / 10.